Role of Tibolone in the prevention and treatment of postmenopausal osteoporosis

By analyzing the values of bone mineral density measured as Tscore value we evaluate the favorable effect of Tibolone in the prevention of postmenopausal osteoporosis and in the variation of bone density in osteoporotic women. We have enrolled 42 post-menopausal women with a mean age of 51.7 years (range 43-58 years) and mean age at menopause of 49.8 years, and we have proposed a hormone replacement therapy with Tibolone (Livial r) 2.5 mg / day. The assessment of bone mineral density was performed at recruitment and after 12 months by DEXA evaluation of BMD and T-score values of the examined sites (lumbar spine and proximal femur) and classified according to WHO criteria. After 12 months a significant reduction in the lumbar spine (P<0.001) and femoral (P<0.05) values of T-score has been shown. In the spine the mean T-score ranged from -1.7 to -1.4 (+17.6%), femoral T-score ranged from -0.8 to -0.7 (+12, 5%). At the lumbar spine the mean values of osteoporotic women ranged from -2.6 to -2.2 with an average increase of 11.5%. This study has shown that Tibolone can prevent bone loss and increase bone mineral density at lumbar spine and proximal femur in postmenopausal women with osteoporosis.